Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem
Two months ago, the narcolepsy therapy Wakix propelled Harmony Biosciences to a $128 million debut on Nasdaq. Now, the same drug is serving as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
